Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21653164 | 0.84 | MAPT (0.37) | MAPTMAPK1FSCN1KMT2AMEN1 | |
| SCHEMBL21653130 | 0.82 | MAPT (0.35) | MAPTMAPK1FSCN1KMT2AMEN1 | |
| SCHEMBL21653148 | 0.81 | MAPT (0.36) | MAPTMAPK1FSCN1KMT2AMEN1 | |
| SCHEMBL21653256 | 0.80 | MAPT (0.34) | MAPTMAPK1FSCN1KMT2AMEN1 | |
| SCHEMBL21653186 | 0.78 | RAB9A (0.40) | MAPTKMT2ATP53ALDH1A1TDP1 | |
| SCHEMBL21653141 | 0.78 | MAPT (0.36) | MAPTMAPK1FSCN1KMT2AMEN1 | |
| SCHEMBL21653244 | 0.76 | BACE1 (0.39) | MAPTMAPK1FSCN1KMT2AMEN1 | |
| SCHEMBL21653074 | 0.76 | GSK3B (0.38) | MAPTMAPK1KMT2AMEN1HSD17B10 | |
| SCHEMBL21653156 | 0.75 | PDE10A (0.38) | MAPTMAPK1KMT2AMEN1TP53 | |
| SCHEMBL21652914 | 0.75 | MAPT (0.31) | MAPTKMT2AMEN1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020023657-A1 | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | Epizyme, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |